Bayer has reported encouraging topline findings from its global phase 3 OCEANIC-STROKE study, evaluating the investigational ...

Asundexian (Bayer) significantly reduces the risk of ischemic stroke compared with placebo, without increasing the risk of ...

Bayer AG said an experimental stroke-prevention drug showed positive results in a late-stage clinical study, a boost for the ...

Bayer’s oral FXIa inhibitor asundexian has significantly reduced the risk of stroke in a phase 3 trial, giving a boost to a potentially blockbuster mechanism that has suffered setbacks over the past ...

Findings are respite for German conglomerate facing sliding sales of blockbuster drugs and US legal challenges ...

Asundexian's Phase 3 study results raise hopes for a new class of cardiovascular drugs that has seen clinical setbacks.

The pharma company said asundexian, when combined with antiplatelet therapy, lowered the risk of stroke in patients during ...

The positive result in OCEANIC-STROKE means that asundexian can potentially now sit alongside prostate cancer therapy Nubeqa ...

Bayer's asundexian hits key goals in the OCEANIC-STROKE study, showing reduced ischemic stroke risk without added major ...

Germany’s Bayer has announced positive top-line results from the global Phase III study OCEANIC-STROKE, with its ...

Bayers experimental stroke treatment, asundexian, delivered strong results in the Phase III OCEANIC-STROKE trial, prompting ...

Bayer stock jumped on Monday after the German healthcare company said a late-stage stroke drug trial achieved its goals.